Expanded Form 5 Five Expanded Form 5 Tips You Need To Learn Now
Alexander, S. P. Ameliorative abeyant of cannabis-related drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 64, 157–166 (2016).
Plasse, T. F. Analytic use of dronabinol. J. Clin. Oncol. 9, 2079–2080 (1991).
Novotna, A. et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design abstraction of nabiximols* (Sativex®), as add-on therapy, in capacity with adverse spasticity acquired by assorted sclerosis. Eur. J. Neurol. 18, 1122–1131 (2011). The analytic abstraction that led to the approval of nabiximols for the assay of MS spasticity.
Keating, G. M. Delta-9-tetrahydrocannabinol/cannabidiol oromucosal aerosol (Sativex®): a assay in assorted sclerosis-related spasticity. Drugs 77, 563–574 (2017).
Mechoulam, R. et al. The anatomy of cannabidiol. Tetrahedron 19, 2073–2078 (1963).
Mechoulam, R. & Gaoni, Y. A absolute amalgam of DL-Δ1-tetrahydrocannabinol, the alive basic of hashish. J. Am. Chem. Soc. 87, 3273–3275 (1965).
Matsuda, L. A. et al. Anatomy of a cannabinoid receptor and anatomic announcement of the cloned cDNA. Nature 346, 561–564 (1990).
Munro, S., Thomas, K. L. & Abu-Shaar, M. Atomic assuming of a borderline receptor for cannabinoids. Nature 365, 61–65 (1993).
Devane, W. A. et al. Isolation and anatomy of a academician basic that binds to the cannabinoid receptor. Science 258, 1946–1949 (1992). The aboriginal abstraction that led to the identification of an autogenous ligand of cannabinoid receptors.
Mechoulam, R. et al. Identification of an autogenous 2-monoglyceride, present in basset gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83–90 (1995).
Sugiura, T. et al. 2-Arachidonoylglycerol: a accessible autogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89–97 (1995).
Di Marzo, V. & Fontana, A. Anandamide, an autogenous cannabinomimetic eicosanoid: ‘killing two birds with one stone’. Prostaglandins Leukot. Essent. Blubbery Acids 53, 1–11 (1995).
Mazzola, C., Micale, V. & Drago, F. Amnesia induced by beta-amyloid bits is counteracted by cannabinoid CB1 receptor blockade. Eur. J. Pharmacol. 47, 219–225 (2003). The aboriginal affirmation that CB1 receptors accord to bookish impairement in a abrasion archetypal of AD.
Cerri, S. et al. Neuroprotective abeyant of adenosine A2A and cannabinoid CB1 receptor antagonists in an beastly archetypal of Parkinson disease. J. Neuropathol. Exp. Neurol. 73, 414–424 (2014).
Lunn, C. A. et al. Biology and ameliorative abeyant of cannabinoid CB2 receptor changed agonists. Br. J. Pharmacol. 153, 226–239 (2008).
Nguyen, T. et al. Allosteric modulation: an alternating access targeting the cannabinoid CB1 receptor. Med. Res. Rev. 37, 441–474 (2017).
Di Marzo, V. New approaches and challenges to targeting the endocannabinoid system. Nat. Rev. Drug Discov. 17, 623–639 (2018).
Lucas, C. J., Galettis, P. & Schneider, J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br. J. Clin. Pharmacol. 84, 2477–2482 (2018).
Abi-Jaoude, E. et al. Preliminary affirmation on cannabis capability and tolerability for adults with Tourette syndrome. J. Neuropsychiatry Clin. Neurosci. 29, 391–400 (2017).
Kerai, A., Sim, T. F. & Emmerton, L. Medical cannabis: a needs assay for bodies with epilepsy. Complement Ther. Clin. Pract. 33, 43–48 (2018).
Stetten, N. et al. The akin of affirmation of medical marijuana use for alleviative disabilities: a scoping review. Disabil. Rehabil. 20, 1–12 (2018).
Adams, R., Pease, D. C., Clark, J. H. & Baker, B. R. Anatomy of cannabinol. I. Preparation of an isomer, 3-hydroxy-1-n-amyl-6,6,9-trimethyl-6-dibenzopyran. J. Am. Chem. Soc. 62, 2197–2200 (1940).
Little, P. J. et al. Pharmacology and stereoselectivity of structurally atypical cannabinoids in mice. J. Pharmacol. Exp. Ther. 247, 1046–1051 (1988).
Beardsley, P. M., Scimeca, J. A. & Martin, B. R. Studies on the agonistic action of basin 9-11-tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with basin 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 241, 521–526 (1987).
Turner, S. E. et al. Atomic pharmacology of phytocannabinoids. Prog. Chem. Org. Nat. Prod. 103, 61–101 (2017).
Mechoulam, R. et al. Chemical base of hashish activity. Science 169, 611–612 (1970).
Devinsky, O. et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 15, 270–278 (2016).
Devinsky, O. et al. Balloon of cannabidiol for drug-resistant seizures in the Dravet syndrome. N. Engl. J. Med. 376, 2011–2020 (2017). One of the analytic trials that led to approval of botanical cannabidiol for the assay of attenuate forms of paediatric epilepsy.
Devane, W. A. et al. Determination and assuming of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605–613 (1988). The aboriginal affirmation for the actuality of a specific bounden armpit for THC.
Bisogno, T. et al. Cloning of the aboriginal sn1-DAG lipases credibility to the spatial and banausic adjustment of endocannabinoid signaling in the brain. J. Corpuscle Biol. 163, 463–468 (2003). Identification of the aboriginal endocannabinoid biosythetic enzymes.
Cravatt, B. F. et al. Atomic assuming of an agitator that degrades neuromodulatory fatty-acid amides. Nature 384, 83–87 (1996). Identification of the aboriginal endocannabinoid-degrading enzyme.
Dinh, T. P. et al. Academician monoglyceride lipase accommodating in endocannabinoid inactivation. Proc. Natl Acad. Sci. USA 99, 10819–10824 (2002).
Okamoto, Y. et al. Atomic assuming of a phospholipase D breeding anandamide and its congeners. J. Biol. Chem. 279, 5298–5305 (2004).
Jung, K. M. et al. An amyloid beta42-dependent arrears in anandamide mobilization is associated with bookish dysfunction in Alzheimer’s disease. Neurobiol. Aging 33, 1522–1532 (2012).
Altamura, C. et al. Acclivity of claret 2-arachidonoylglycerol levels in Alzheimer’s ache patients as a abeyant careful apparatus adjoin neurodegenerative decline. J. Alzheimers Dis. 46, 497–506 (2015).
Di Iorio et al. The endocannabinoid system: a accepted role in neurodegenerative diseases. Int. J. High Risk Behav. Addict. 2, 100–106 (2013).
Aymerich, M. S. et al. Cannabinoid pharmacology/therapeutics in abiding degenerative disorders affecting the axial afraid system. Biochem. Pharmacol. 157, 67–84 (2018).
Mulder, J. et al. Atomic about-face of endocannabinoid signalling in Alzheimer’s disease. Academician 134, 1041–1060 (2011). The aboriginal atomic affirmation that endocannabinoid signalling ability be overactive in AD.
Celorrio, M. et al. Blubbery acerbic amide hydrolase inhibition for the appropriate abatement of Parkinson’s disease. Academician Behav. Immun. 57, 94–105 (2016).
D’Addario, C. et al. Epigenetic adjustment of blubbery acerbic amide hydrolase in Alzheimer disease. PLOS ONE 7, e39186 (2012).
Bilsland, L. G. et al. Increasing cannabinoid levels by pharmacological and abiogenetic abetment adjournment ache progression in SOD1 mice. FASEB J. 20, 1003–1005 (2006).
Di Marzo, V. Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov. 7, 438–455 (2008).
Kawahara, H. et al. Inhibition of blubbery acerbic amide hydrolase unmasks CB1 receptor and TRPV1 channel-mediated accentuation of glutamatergic synaptic manual in midbrain periaqueductal grey. Br. J. Pharmacol. 163, 1214–1222 (2011).
Benito, C. et al. beta-Amyloid exacerbates deepening in astrocytes abnormal blubbery acerbic amide hydrolase through a apparatus involving PPAR-alpha, PPAR-gamma and TRPV1, but not CB(1) or CB(2) receptors. Br. J. Pharmacol. 166, 1474–1489 (2012).
Hansen, H. S. et al. GPR119 as a fat sensor. Trends. Pharmacol. Sci. 33, 374–381 (2012).
Luchicchi, A. et al. Furnishings of blubbery acerbic amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the basis accumbens carapace and belly tegmental area: captivation of PPAR-alpha nuclear receptors. Addict. Biol. 15, 277–288 (2010).
Blankman, J. L., Simon, G. M. & Cravatt, B. F. A absolute contour of academician enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14, 1347–1356 (2007).
Zygmunt, P. M. et al. Monoacylglycerols actuate TRPV1–a articulation amid phospholipase C and TRPV1. PLOS ONE 8, e81618 (2013).
Kozak, K. R., Prusakiewicz, J. J. & Marnett, L. J. Oxidative metabolism of endocannabinoids by COX-2. Curr. Pharm. Des. 10, 659–667 (2004).
Valdeolivas, S. et al. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than acceptable striatal damage, protects striatal neurons from malonate-induced death: a abeyant role of cyclooxygenase-2-dependent metabolism of 2-AG. Corpuscle Afterlife Dis. 4, e862 (2013).
Liang, Y. et al. Identification and pharmacological assuming of the prostaglandin FP receptor and FP receptor another complexes. Br. J. Pharmacol. 154, 1079–1093 (2008).
Nakane, S. et al. 2-Arachidonoyl-sn-glycero-3-phosphate, an arachidonic acid-containing lysophosphatidic acid: accident and accelerated enzymatic about-face to 2-arachidonoyl-sn-glycerol, a cannabinoid receptor ligand, in rat brain. Arch. Biochem. Biophys. 402, 51–58 (2002).
Tsuboi, K. et al. Predominant announcement of lysosomal N-acylethanolamine-hydrolyzing acerbic amidase in macrophages appear by immunochemical studies. Biochim. Biophys. Acta 1771, 623–632 (2007).
Navia-Paldanius, D. et al. Added analeptic cannabinoid CB1R action and academician region-specific desensitization of CB1R Gi/o signaling arbor in mice with all-around abiogenetic knockout of monoacylglycerol lipase. Eur. J. Pharm. Sci. 77, 180–188 (2015).
Imperatore, R. et al. Abiogenetic abatement of monoacylglycerol lipase leads to broken cannabinoid receptor CB(1)R signaling and anxiety-like behavior. J. Neurochem. 135, 799–813 (2015).
Nomura, D. K. et al. Monoacylglycerol lipase exerts bifold ascendancy over endocannabinoid and blubbery acerbic pathways to abutment prostate cancer. Chem. Biol. 18, 846–856 (2011).
Piro, J. R. et al. A dysregulated endocannabinoid-eicosanoid arrangement supports pathogenesis in a abrasion archetypal of Alzheimer’s disease. Cell. Rep. 1, 617–623 (2012).
Saghatelian, A. et al. A FAAH-regulated chic of N-acyl taurines that activates TRP ion channels. Biochemistry 45, 9007–9015 (2006).
Verhoeckx, K. C. et al. Presence, accession and accepted biological activities of N-acyl serotonins, a atypical chic of fatty-acid acquired mediators, in the abdominal tract. Biochim. Biophys. Acta 1811, 578–586 (2011). Identification of N-acyl-serotonins, endocannabinoidome molecules with a bifold apparatus of action.
Chu, C. J. et al. N-oleoyldopamine, a atypical autogenous capsaicin-like lipid that produces hyperalgesia. J. Biol. Chem. 278, 13633–13639 (2003).
Di Marzo, V. & Wang, J. (eds) The Endocannabinoidome: The World of Endocannabinoids and Related Mediators (Elsevier, 2015).
Morales, P., Goya, P. & Jagerovic, N. Emerging strategies targeting CB2 cannabinoid receptor: biased agonism and allosterism. Biochem. Pharmacol. 157, 8–17 (2018).
Dopart, R. et al. Allosteric modulators of cannabinoid receptor 1: developing compounds for bigger specificity. Drug Metab. Rev. 50, 3–13 (2018).
Bauer, M. et al. Identification and altitude of a new ancestors of peptide endocannabinoids (Pepcans) assuming abrogating allosteric accentuation at CB1 receptors. J. Biol. Chem. 287, 36944–36967 (2012). Identification of the aboriginal autogenous peptidic allosteric modulators of cannabinoid receptors.
Pamplona, F. A. et al. Anti-inflammatory lipoxin A4 is an autogenous allosteric enhancer of CB1 cannabinoid receptor. Proc. Natl Acad. Sci. USA 109, 21134–21139 (2012).
Vallee, M. et al. Pregnenolone can assure the academician from cannabis intoxication. Science 343, 94–98 (2014).
Cristino, L., Imperatore, R. & Di Marzo, V. Techniques for the cellular and subcellular localization of endocannabinoid receptors and enzymes in the beastly brain. Methods. Enzymol. 593, 61–98 (2017).
Hu, S. S. & Mackie, K. Administering of the endocannabinoid arrangement in the axial afraid system. Handb. Exp. Pharmacol. 231, 59–93 (2015).
Katona, I. & Freund, T. F. Endocannabinoid signaling as a synaptic ambit breaker in acoustic disease. Nat. Med. 14, 923–930 (2008).
Matyas, F. et al. Identification of the sites of 2-arachidonoylglycerol amalgam and action betoken astern endocannabinoid signaling at both GABAergic and glutamatergic synapses in the belly tegmental area. Neuropharmacology 54, 95–107 (2008).
Wilson, R. I. & Nicoll, R. A. Autogenous cannabinoids arbitrate astern signalling at hippocampal synapses. Nature 410, 588–592 (2001). The aboriginal affirmation that CB1 and endocannabinoids act as astern neuromodulators of synaptic plasticity.
Araque, A. et al. Synaptic functions of endocannabinoid signaling in bloom and disease. Neuropharmacology 124, 13–24 (2017).
Marinelli, S. et al. The endocannabinoid 2-arachidonoylglycerol is amenable for the apathetic self-inhibition in neocortical interneurons. J. Neurosci. 28, 13532–13541 (2008).
Koch, M. et al. Hypothalamic POMC neurons advance cannabinoid-induced feeding. Nature 519, 45–50 (2015).
Morello, G. et al. Orexin-A represses satiety-inducing POMC neurons and contributes to blubber via dispatch of endocannabinoid signaling. Proc. Natl Acad. Sci. USA 113, 4759–4764 (2016).
Benard, G. et al. Mitochondrial CB(1) receptors adapt neuronal action metabolism. Nat. Neurosci. 15, 558–564 (2012). Identification of accepted mitochondrial CB1 receptors.
Hebert-Chatelain, E. et al. A cannabinoid articulation amid mitochondria and memory. Nature 539, 555–559 (2016).
Bosier, B. et al. Astroglial CB1 cannabinoid receptors adapt leptin signaling in abrasion academician astrocytes. Mol. Metab. 2, 393–404 (2013).
Robin, L. M. et al. Astroglial CB1 receptors actuate synaptic D-serine availability to accredit acceptance memory. Neuron 98, 935–944.e5 (2018).
Prenderville, J. A., Kelly, Á. M. & Downer, E. J. The role of cannabinoids in developed neurogenesis. Br. J. Pharmacol. 172, 3950–3963 (2015).
Cassano, T. et al. Cannabinoid receptor 2 signaling in neurodegenerative disorders: from pathogenesis to a able ameliorative target. Front. Neurosci. 11, 30 (2017).
Palazuelos, J. et al. CB2 cannabinoid receptors advance neural antecedent corpuscle admeasurement via mTORC1 signaling. J. Biol. Chem. 287, 1198–1209 (2012).
Chung, Y. C. et al. CB2 receptor activation prevents glial-derived neurotoxic advocate production, BBB arising and borderline allowed corpuscle aggression and rescues dopamine neurons in the MPTP archetypal of Parkinson’s disease. Exp. Mol. Med. 48, e205 (2016).
Xi, Z. X. et al. Academician cannabinoid CB(2) receptors attune cocaine’s accomplishments in mice. Nat. Neurosci. 14, 1160–1166 (2011).
Navarrete, F. et al. Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and concrete furnishings of nicotine. Neuropsychopharmacology 38, 2515–2524 (2013).
Marchalant, Y. et al. Validating antibodies to the cannabinoid CB2 receptor: antibiotic acuteness is not affirmation of antibiotic specificity. J. Histochem. Cytochem. 62, 395–404 (2014).
Soethoudt, M. et al. Cannabinoid CB2 receptor ligand profiling reveals biased signalling and astray activity. Nat. Commun. 8, 13958 (2017).
Stempel, A. V. et al. Cannabinoid blazon 2 receptors arbitrate a corpuscle type-specific bendability in the hippocampus. Neuron 90, 795–809 (2016). The aboriginal atomic abstraction to advance a apparatus of action for CB2 receptors in neurons.
Cristino, L. et al. Immunohistochemical localization of cannabinoid blazon 1 and vanilloid brief receptor abeyant vanilloid blazon 1 receptors in the abrasion brain. Neuroscience 139, 1405–1415 (2006).
Cristino, L. et al. Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and added accepted endovanilloids in the hippocampus and cerebellar case of the abrasion brain. Neuroscience 151, 955–968 (2008).
Edwards, J. G. TRPV1 in the axial afraid system: synaptic plasticity, function, and pharmacological implications. Prog. Drug Res. 68, 77–104 (2014).
Sun, F. J. et al. Added announcement of TRPV1 in the case and hippocampus from patients with mesial banausic affiliate epilepsy. J. Mol. Neurosci. 49, 182–193 (2013).
Bhaskaran, M. D. & Smith, B. N. Cannabinoid-mediated inhibition of alternate excitatory chip in the dentate gyrus in a abrasion archetypal of banausic affiliate epilepsy. PLOS ONE 5, e10683 (2010).
Chavez, A. E., Chiu, C. Q. & Castillo, P. E. TRPV1 activation by autogenous anandamide triggers postsynaptic abiding abasement in dentate gyrus. Nat. Neurosci. 13, 1511–1518 (2010). Important affirmation for a anatomic role of TRPV1 in neurons.
Marrone, M. C. et al. TRPV1 channels are analytical academician deepening detectors and neuropathic affliction biomarkers in mice. Nat. Commun. 10, 15292 (2017).
Stampanoni Bassi, M. et al. Brief receptor abeyant vanilloid 1 modulates axial deepening in assorted sclerosis. Front. Neurol. 10, 30 (2019).
Villapol, S. Roles of peroxisome proliferator-activated receptor gamma on academician and borderline inflammation. Corpuscle Mol. Neurobiol. 38, 121–132 (2018).
Blednov, Y. A. et al. Peroxisome proliferator-activated receptors alpha and gamma are affiliated with booze burning in mice and abandonment and assurance in humans. Booze Clin. Exp. Res. 39, 136–145 (2015).
Donvito, G. et al. N-oleoyl-glycine reduces nicotine accolade and abandonment in mice. Neuropharmacology 148, 320–331 (2018). Identification of an autogenous nicotine anti-additive molecule.
Laleh, P. et al. Oleoylethanolamide increases the announcement of PPAR-alpha and reduces appetence and anatomy weight in adipose people: a analytic trial. Appetence 128, 44–49 (2018).
Quintanilla, R. A., Utreras, E. & Cabezas-Opazo, F. A. Role of PPAR gamma in the adverse and action of neurons. PPAR Res. 2014, 768594 (2014).
Sylantyev, S. et al. Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter absolution at axial synapses. Proc. Natl Acad. Sci. USA 110, 5193–5198 (2013).
Kaplan, J. S. et al. Cannabidiol attenuates seizures and amusing deficits in a abrasion archetypal of Dravet syndrome. Proc. Natl Acad. Sci. USA 114, 11229–11234 (2017).
McHugh, D. et al. siRNA altercation of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycine-induced corpuscle migration. J. Mol. Signal. 7, 10 (2012).
Penumarti, A. & Abdel-Rahman, A. A. The atypical endocannabinoid receptor GPR18 is bidding in the rostral ventrolateral medulla and exerts analeptic abstinent access on claret pressure. J. Pharmacol. Exp. Ther. 349, 29–38 (2014).
Sharkey, K. A. & Wiley, J. W. The role of the endocannabinoid arrangement in the brain-gut axis. Gastroenterology 151, 252–266 (2016).
Cani, P. D. et al. Endocannabinoids–at the capital amid the gut microbiota and host metabolism. Nat. Rev. Endocrinol. 12, 133–143 (2016).
Muccioli, G. G. et al. The endocannabinoid arrangement links gut microbiota to adipogenesis. Mol. Syst. Biol. 6, 392 (2010). One of the aboriginal studies to articulation the endocannabinoid arrangement with the gut microbiota.
Mehrpouya-Bahrami, P. et al. Barricade of CB1 cannabinoid receptor alters gut microbiota and attenuates deepening and diet-induced obesity. Sci. Rep. 7, 15645 (2017).
Guida, F. et al. Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial about-face and abasement in mice. Academician Behav. Immun. 67, 230–245 (2018). Analysis of the abeyant role of abdominal N-acyl-serotonins in antibiotic-induced depression.
Rousseaux, C. et al. Lactobacillus acidophilus modulates abdominal affliction and induces opioid and cannabinoid receptors. Nat. Med. 13, 35–37 (2007). Identification of an important abeyant articulation amid probiotic ameliorative furnishings and the endocannabinoid system.
Geurts, L. et al. Adipose tissue NAPE-PLD controls fat accession development by altering the browning action and gut microbiota. Nat. Commun. 6, 6495 (2015).
Janakiraman, M. & Krishnamoorthy, G. Emerging role of diet and microbiota interactions in neuroinflammation. Front. Immunol. 9, 2067 (2018).
Garcia-Arencibia, M. et al. Cannabinoid CB1 receptors are aboriginal downregulated followed by a added upregulation in the basal ganglia of mice with abatement of specific PARK genes. J. Neural Transm. Suppl. 73, 269–275 (2009).
Walsh, S. et al. Loss of cannabinoid CB1 receptor announcement in the 6-hydroxydopamine-induced nigrostriatal terminal bane archetypal of Parkinson’s ache in the rat. Academician Res. Bull. 81, 543–548 (2010).
Rojo-Bustamante, E. et al. The announcement of cannabinoid blazon 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is adapted in basal ganglia during the alive actualization of levodopa-induced dyskinesia. Neurobiol. Dis. 118, 64–75 (2018).
Van Laere, K. et al. Regional changes in blazon 1 cannabinoid receptor availability in Parkinson’s ache in vivo. Neurobiol. Aging 33, 620.e1–620.e8 (2012).
Navarrete, F. et al. Cannabinoid CB1 and CB2 receptors, and monoacylglycerol lipase gene announcement alterations in the basal ganglia of patients with Parkinson’s disease. Neurotherapeutics 15, 459–469 (2018).
Gomez-Galvez, Y. et al. Abeyant of the cannabinoid CB(2) receptor as a pharmacological ambition adjoin deepening in Parkinson’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 64, 200–208 (2016).
Morgese, M. G. et al. Anti-dyskinetic furnishings of cannabinoids in a rat archetypal of Parkinson’s disease: role of CB(1) and TRPV1 receptors. Exp. Neurol. 208, 110–119 (2007).
Fox, S. H. et al. Dispatch of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman abbey archetypal of Parkinson’s disease. Mov. Disord. 17, 1180–1187 (2002).
van der Stelt, M. et al. A role for endocannabinoids in the bearing of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human abbey models of Parkinson’s disease. FASEB J. 19, 1140–1142 (2005).
Fernandez-Espejo, E. et al. Cannabinoid CB1 antagonists acquire antiparkinsonian ability alone in rats with actual astringent nigral bane in beginning parkinsonism. Neurobiol. Dis. 18, 591–601 (2005).
Cao, X. et al. Barricade of cannabinoid blazon 1 receptors augments the antiparkinsonian action of levodopa afterwards affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J. Pharmacol. Exp. Ther. 323, 318–326 (2007).
Garcia-Arencibia, M. et al. Appraisal of the neuroprotective aftereffect of cannabinoids in a rat archetypal of Parkinson’s disease: accent of antioxidant and cannabinoid receptor-independent properties. Academician Res. 1134, 162–170 (2007).
Shi, J. et al. AM1241 alleviates MPTP-induced Parkinson’s ache and promotes the about-face of DA neurons in PD mice. Oncotarget 8, 67837–67850 (2017).
Pisani, A. et al. High autogenous cannabinoid levels in the cerebrospinal aqueous of basic Parkinson’s ache patients. Ann. Neurol. 57, 777–779 (2005). The aboriginal abstracts from beastly studies on the abeyant dysregulation of endocannabinoids in PD.
Gubellini, P. et al. Beginning parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 22, 6900–6907 (2002).
Di Marzo, V. et al. Enhanced levels of autogenous cannabinoids in the globus pallidus are associated with a abridgement in movement in an beastly archetypal of Parkinson’s disease. FASEB J. 14, 1432–1438 (2000). The aboriginal affirmation for a role of endocannabinoids in PD.
Pisani, V. et al. Dynamic changes of anandamide in the cerebrospinal aqueous of Parkinson’s ache patients. Mov. Disord. 25, 920–924 (2010).
Fernandez-Suarez, D. et al. Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial corpuscle phenotype in the abiding MPTP abrasion model. Neurobiol. Aging 35, 2603–2616 (2014).
Esposito, E. et al. Neuroprotective activities of palmitoylethanolamide in an beastly archetypal of Parkinson’s disease. PLOS ONE 7, e41880 (2012).
Gonzalez-Aparicio, R. & Moratalla, R. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a abrasion archetypal of Parkinson s disease. Neurobiol. Dis. 62, 416–425 (2014).
Lastres-Becker, I. et al. Cannabinoids accommodate neuroprotection adjoin 6-hydroxydopamine toxicity in vivo and in vitro: appliance to Parkinson’s disease. Neurobiol. Dis. 19, 96–107 (2005).
Garcia, C. et al. Symptom-relieving and neuroprotective furnishings of the phytocannabinoid delta(9)-THCV in beastly models of Parkinson’s disease. Br. J. Pharmacol. 163, 1495–1506 (2011).
Chagas, M. H. et al. Furnishings of cannabidiol in the assay of patients with Parkinson’s disease: an basic double-blind trial. J. Psychopharmacol. 28, 1088–1098 (2014).
Sieradzan, K. A. et al. Cannabinoids abate levodopa-induced dyskinesia in Parkinson’s disease: a pilot study. Neurology 57, 2108–2111 (2001).
Brotini, S., S.C., Schievano, C. & Guidi, L. Ultra-micronized palmitoylethanolamide: an active accessory assay for Parkinson’s disease. CNS Neurol. Disord. Drug Targets 16, 705–713 (2017).
Petrosino, S. & Di Marzo, V. The pharmacology of palmitoylethanolamide and aboriginal abstracts on the ameliorative ability of some of its new formulations. Br. J. Pharmacol. 174, 1349–1365 (2017).
Karkkaine, E., Tanila, H. & Laitinen, J. T. Anatomic autoradiography shows changeless cannabinoid CB1 receptor signalling in hippocampus and case of APP/PS1 transgenic mice. CNS Neurol. Disord. Drug Targets 11, 1038–1044 (2012).
Maccarrone, M. et al. Aboriginal about-face of administering and action of hippocampal type-1 cannabinoid receptor in Alzheimer’s disease-like mice overexpressing the beastly aberrant amyloid forerunner protein. Pharmacol. Res. 130, 366–373 (2018).
Aso, E. et al. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AbetaPP/PS1 mice. J. Alzheimers Dis. 35, 847–858 (2013).
Ramirez, B. G. et al. Prevention of Alzheimer’s ache anatomy by cannabinoids: neuroprotection advised by barricade of microglial activation. J. Neurosci. 25, 1904–1913 (2005).
Martin-Moreno, A. M. et al. Cannabidiol and added cannabinoids abate microglial activation in vitro and in vivo: appliance to Alzheimer’s disease. Mol. Pharmacol. 79, 964–973 (2011).
Westlake, T. M. et al. Cannabinoid receptor bounden and abettor RNA announcement in beastly brain: an in vitro receptor autoradiography and in situ admixture histochemistry abstraction of accustomed age-old and Alzheimer’s brains. Neuroscience 63, 637–652 (1994).
Lee, J. H. et al. Intact cannabinoid CB1 receptors in the Alzheimer’s ache cortex. Neurochem. Int. 57, 985–989 (2010).
Ahmad, R. et al. In vivo blazon 1 cannabinoid receptor availability in Alzheimer’s disease. Eur. Neuropsychopharmacol. 24, 242–250 (2014).
Manuel, I. et al. Type-1 cannabinoid receptor action during Alzheimer’s ache progression. J. Alzheimers Dis. 42, 761–766 (2014).
Esposito, G. et al. Opposing ascendancy of cannabinoid receptor dispatch on amyloid-beta-induced acknowledging gliosis: in vitro and in vivo evidence. J. Pharmacol. Exp. Ther. 322, 1144–1152 (2007).
Lopez, A. et al. Cannabinoid CB2 receptors in the abrasion brain: appliance for Alzheimer’s disease. J. Neuroinflammation 15, 158 (2018).
Sheng, W. S. et al. Synthetic cannabinoid WIN55,212-2 inhibits bearing of anarchic mediators by IL-1beta-stimulated beastly astrocytes. Glia 49, 211–219 (2005).
Ehrhart, J. et al. Dispatch of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation 2, 29 (2005).
Walter, L. et al. Nonpsychotropic cannabinoid receptors adapt microglial corpuscle migration. J. Neurosci. 23, 1398–1405 (2003).
Koppel, J. et al. CB2 receptor absence increases amyloid anatomy and alters tau processing in a transgenic abrasion archetypal of Alzheimer’s disease. Mol. Med. 20, 29–36 (2014).
Benito, C. et al. Cannabinoid CB2 receptors and blubbery acerbic amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s ache brains. J. Neurosci. 23, 11136–11141 (2003). The aboriginal affirmation that the endocannabinoid arrangement is adapted in post-mortem accuracy from patients with AD.
Vazquez, C. et al. Endocannabinoid adjustment of amyloid-induced neuroinflammation. Neurobiol. Aging 36, 3008–3019 (2015).
van der Stelt, M. et al. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: aftereffect of pharmacological acclivity of endocannabinoid levels. Corpuscle Mol. Life Sci. 63, 1410–1424 (2006).
Chen, R. et al. Monoacylglycerol lipase is a ameliorative ambition for Alzheimer’s disease. Corpuscle Rep. 2, 1329–1339 (2012).
Zhang, J. & Chen, C. Alleviation of neuropathology by inhibition of monoacylglycerol lipase in APP transgenic mice abnormal CB2 receptors. Mol. Neurobiol. 55, 4802–4810 (2018).
Pihlaja, R. et al. Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory acknowledgment in APdE9 mice and in developed abrasion glial cells. J. Neuroinflammation 12, 81 (2015).
D’Agostino, G. et al. Palmitoylethanolamide protects adjoin the amyloid-beta25-35-induced acquirements and anamnesis crime in mice, an beginning archetypal of Alzheimer disease. Neuropsychopharmacology 37, 1784–1792 (2012).
Bronzuoli, M. R. et al. Palmitoylethanolamide dampens acknowledging astrogliosis and improves neuronal trophic abutment in a amateur transgenic archetypal of Alzheimer’s disease: in vitro and in vivo evidence. Oxid. Med. Cell. Longev. 2018, 4720532 (2018).
Esposito, G. et al. The marijuana basic cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin alleyway accomplishment in PC12 cells. J. Mol. Med. 84, 253–258 (2006).
Cheng, D. et al. Abiding cannabidiol assay prevents the development of amusing acceptance anamnesis deficits in Alzheimer’s ache transgenic mice. J. Alzheimers Dis. 42, 1383–1396 (2014).
Aso, E. et al. Cannabis-based anesthetic reduces assorted anatomization processes in AbetaPP/PS1 mice. J. Alzheimers Dis. 43, 977–991 (2015).
Passmore, M. J. The cannabinoid receptor agonist nabilone for the assay of dementia-related agitation. Int. J. Geriatr. Psychiatry 23, 116–117 (2008).
van den Elsen, G. A. et al. Tetrahydrocannabinol for neuropsychiatric affection in dementia: a randomized controlled trial. Neurology 84, 2338–2346 (2015).
van den Elsen, G. A. H. et al. Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial. Am. J. Geriatr. Psychiatry 23, 1214–1224 (2015).
van den Elsen, G. A. et al. Furnishings of tetrahydrocannabinol on antithesis and amble in patients with dementia: a randomised controlled crossover trial. J. Psychopharmacol. 31, 184–191 (2017).
Denovan-Wright, E. M. & Robertson, H. A. Cannabinoid receptor abettor RNA levels abatement in a subset of neurons of the crabbed striatum, case and hippocampus of transgenic Huntington’s ache mice. Neuroscience 98, 705–713 (2000).
Lastres-Becker, I. et al. Loss of mRNA levels, bounden and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic archetypal of Huntington’s disease. Academician Res. 929, 236–242 (2002).
Dowie, M. J. et al. Adapted CB1 receptor and endocannabinoid levels announce motor affirmation access in a transgenic abrasion archetypal of Huntington’s disease. Neuroscience 163, 456–465 (2009).
Glass, M., Faull, R. L. & Dragunow, M. Loss of cannabinoid receptors in the substantia nigra in Huntington’s disease. Neuroscience 56, 523–527 (1993). The aboriginal affirmation for abnormal endocannabinoid signalling in post-mortem accuracy from patients with HD.
Monory, K. et al. Abiogenetic anatomization of behavioural and autonomic furnishings of delta(9)-tetrahydrocannabinol in mice. PLOS Biol. 5, e269 (2007).
Chiarlone, A. et al. A belted citizenry of CB1 cannabinoid receptors with neuroprotective activity. Proc. Natl Acad. Sci. USA 111, 8257–8262 (2014). Identification that CB1 receptors in alone glutamatergic neurons accept a neuroprotective role in HD.
Ruiz-Calvo, A. et al. Pathway-specific ascendancy of striatal neuron vulnerability by corticostriatal cannabinoid CB1 receptors. Cereb. Case 28, 307–322 (2018).
Mievis, S., Blum, D. & Ledent, C. Worsening of Huntington ache phenotype in CB1 receptor knockout mice. Neurobiol. Dis. 42, 524–529 (2011).
Palazuelos, J. et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s ache excitotoxicity. Academician 132, 3152–3164 (2009).
Bouchard, J. et al. Cannabinoid receptor 2 signaling in borderline allowed beef modulates ache access and severity in abrasion models of Huntington’s disease. J. Neurosci. 32, 18259–18268 (2012).
Sagredo, O. et al. Cannabinoid CB2 receptor agonists assure the striatum adjoin malonate toxicity: appliance for Huntington’s disease. Glia 57, 1154–1167 (2009).
Pietropaolo, S. et al. Abiding cannabinoid receptor dispatch selectively prevents motor impairments in a abrasion archetypal of Huntington’s disease. Neuropharmacology 89, 368–374 (2015).
Bisogno, T. et al. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in academician areas of R6/2 mice, a transgenic archetypal of Huntington’s disease. Neurochem. Int. 52, 307–313 (2008).
Bari, M. et al. In vitro and in vivo models of Huntington’s ache actualization alterations in the endocannabinoid system. FEBS J. 280, 3376–3388 (2013).
Battista, N. et al. Astringent absence of the blubbery acerbic amide hydrolase (FAAH) action segregates with the Huntington’s ache alteration in borderline lymphocytes. Neurobiol. Dis. 27, 108–116 (2007).
Lastres-Becker, I. et al. Compounds acting at the endocannabinoid and/or endovanilloid systems abate hyperkinesia in a rat archetypal of Huntington’s disease. J. Neurochem. 84, 1097–1109 (2003).
Sagredo, O. et al. Cannabidiol bargain the striatal decline acquired 3-nitropropionic acerbic in vivo by mechanisms absolute of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur. J. Neurosci. 26, 843–851 (2007).
Valdeolivas, S. et al. Neuroprotective backdrop of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 12, 185–199 (2015).
Sagredo, O., Pazos, M. R., Valdeolivas, S. & Fernandez-Ruiz, J. Cannabinoids: atypical medicines for the assay of Huntington’s disease. Recent Pat. CNS Drug Discov. 7, 41–48 (2012).
Lopez-Sendon Moreno, J. L. et al. A double-blind, randomized, cross-over, placebo-controlled, pilot balloon with Sativex in Huntington’s disease. J. Neurol. 263, 1390–1400 (2016).
Saft, C. et al. Cannabinoids for assay of dystonia in Huntington’s disease. J. Huntingt. Dis. 7, 167–173 (2018).
Consroe, P. et al. Controlled analytic balloon of cannabidiol in Huntington’s disease. Pharmacol. Biochem. Behav. 40, 701–708 (1991).
Curtis, A. et al. A pilot abstraction appliance nabilone for appropriate assay in Huntington’s disease. Mov. Disord. 24, 2254–2259 (2009).
Muller-Vahl, K. R. et al. Assay of Tourette’s affection with delta-9-tetrahydrocannabinol. Am. J. Psychiatry 156, 495 (1999). The aboriginal affirmation that THC ability accept benign aftereffect in Tourette syndrome.
Cabranes, A. et al. Decreased endocannabinoid levels in the academician and benign furnishings of agents activating cannabinoid and/or vanilloid receptors in a rat archetypal of assorted sclerosis. Neurobiol. Dis. 20, 207–217 (2005).
Cabranes, A. et al. Changes in CB1 receptors in motor-related academician structures of abiding relapsing beginning allergic encephalomyelitis mice. Academician Res. 1107, 199–205 (2006).
Benito, C. et al. Cannabinoid CB1 and CB2 receptors and blubbery acerbic amide hydrolase are specific markers of applique corpuscle subtypes in beastly assorted sclerosis. J. Neurosci. 27, 2396–2402 (2007).
Loria, F. et al. Abstraction of the adjustment of the endocannabinoid arrangement in a virus archetypal of assorted sclerosis reveals a ameliorative aftereffect of palmitoylethanolamide. Eur. J. Neurosci. 28, 633–641 (2008).
Jean-Gilles, L. et al. Claret endocannabinoid levels in assorted sclerosis. J. Neurol. Sci. 287, 212–215 (2009).
Baker, D. et al. Cannabinoids ascendancy spasticity and agitation in a assorted sclerosis model. Nature 404, 84–87 (2000). The aboriginal abstraction to authenticate that CB1 receptors accept a role in the ascendancy of MS spasticity.
Baker, D. et al. Endocannabinoids ascendancy spasticity in a assorted sclerosis model. FASEB J. 15, 300–302 (2001). The aboriginal abstraction to advance that careful academician and analgesic bond endocannabinoids are produced in alongside with the actualization of spasticity in an MS model.
Arevalo-Martin, A. et al. Ameliorative action of cannabinoids in a murine archetypal of assorted sclerosis. J. Neurosci. 23, 2511–2516 (2003).
Arevalo-Martin, A., Molina-Holgado, E. & Guaza, C. A. CB(1)/CB(2) receptor agonist, WIN 55,212-2, exerts its ameliorative aftereffect in a viral autoimmune archetypal of assorted sclerosis by abating self-tolerance to myelin. Neuropharmacology 63, 385–393 (2012).
Maresz, K. et al. Direct abolishment of CNS autoimmune deepening via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 13, 492–497 (2007). The analysis of two adapted careful roles of CB1 and CB2 in a archetypal of MS.
Sanchez Lopez, A. J. et al. Adjustment of cannabinoid receptor gene announcement and endocannabinoid levels in lymphocyte subsets by interferon-beta: a longitudinal abstraction in assorted sclerosis patients. Clin. Exp. Immunol. 179, 119–127 (2015).
Musella, A. et al. Pre- and postsynaptic type-1 cannabinoid receptors ascendancy the alterations of glutamate manual in beginning autoimmune encephalomyelitis. Neuropharmacology 79, 567–572 (2014).
Centonze, D. et al. The endocannabinoid arrangement is dysregulated in assorted sclerosis and in beginning autoimmune encephalomyelitis. Academician 130, 2543–2553 (2007). The analysis that endocannabinoid levels are adapted in patients with MS.
Di Filippo, M. et al. Abnormalities in the cerebrospinal aqueous levels of endocannabinoids in assorted sclerosis. J. Neurol. Neurosurg. Psychiatry. 79, 1224–1229 (2008).
de Lago, E. et al. UCM707, an inhibitor of the anandamide uptake, behaves as a affirmation ascendancy abettor in models of Huntington’s ache and assorted sclerosis, but fails to delay/arrest the progression of adapted motor-related disorders. Eur. Neuropsychopharmacol. 16, 7–18 (2006).
Loria, F. et al. An endocannabinoid accent banned excitotoxicity in vitro and in a archetypal of assorted sclerosis. Neurobiol. Dis. 37, 166–176 (2010).
Pryce, G. et al. Ascendancy of beginning spasticity by targeting the abasement of endocannabinoids appliance careful blubbery acerbic amide hydrolase inhibitors. Mult. Scler. 19, 1896–1904 (2013).
Brindisi, M. et al. Development and pharmacological assuming of careful blockers of 2-arachidonoyl glycerol abasement with ability in rodent models of assorted sclerosis and pain. J. Med. Chem. 59, 2612–2632 (2016).
Wen, J. et al. Activation of CB2 receptor is appropriate for the ameliorative aftereffect of ABHD6 inhibition in beginning autoimmune encephalomyelitis. Neuropharmacology 99, 196–209 (2015).
Rahimi, A. et al. Interaction amid the careful furnishings of cannabidiol and palmitoylethanolamide in beginning archetypal of assorted sclerosis in C57BL/6 mice. Neuroscience 290, 279–287 (2015).
Kozela, E. et al. Cannabidiol inhibits pathogenic T cells, decreases analgesic microglial activation and ameliorates assorted sclerosis-like ache in C57BL/6 mice. Br. J. Pharmacol. 163, 1507–1519 (2011).
Giacoppo, S., Bramanti, P. & Mazzon, E. Sativex in the administering of assorted sclerosis-related spasticity: an overview of the aftermost decade of analytic evaluation. Mult. Scler. Relat. Disord. 17, 22–31 (2017).
Mecha, M. et al. Cannabidiol provides abiding aegis adjoin the deleterious furnishings of deepening in a viral archetypal of assorted sclerosis: a role for A2A receptors. Neurobiol. Dis. 59, 141–150 (2013).
Hilliard, A. et al. Appraisal of the furnishings of sativex (THC BDS: CBD BDS) on inhibition of spasticity in a abiding relapsing beginning allergic autoimmune encephalomyelitis: a archetypal of assorted sclerosis. ISRN Neurol. 2012, 802649 (2012).
Markova, J. et al. Sativex® as add-on assay vs. added optimized first-line ANTispastics (SAVANT) in aggressive assorted sclerosis spasticity: a double-blind, placebo-controlled randomised analytic trial. Int. J. Neurosci. 129, 119–128 (2018).
Koch, G. et al. Cannabis-based assay induces polarity-reversing bendability adjourned by theta access dispatch in humans. Academician Stimul. 2, 229–233 (2009).
Carotenuto, A. et al. Upper motor neuron appraisal in assorted sclerosis patients advised with Sativex®. Acta Neurol. Scand. 135, 442–448 (2017).
Russo, M. et al. Sativex in the administering of assorted sclerosis-related spasticity: role of the corticospinal modulation. Neural Plast. 2015, 656582 (2015).
Turri, M. et al. Affliction accentuation afterwards oromucosal cannabinoid aerosol (SATIVEX®) in patients with assorted sclerosis: a abstraction with quantitative acoustic testing and laser-evoked potentials. Medicines 5, 59 (2018).
Messina, S. et al. Sativex in aggressive assorted sclerosis spasticity: cessation abstraction in a ample citizenry of Italian patients (SA.FE. study). PLOS ONE 12, e0180651 (2017).
Patti, F. et al. Ability and assurance of cannabinoid oromucosal aerosol for assorted sclerosis spasticity. J. Neurol. Neurosurg. Psychiatry 87, 944–951 (2016).
Sorosina, M. et al. Analytic acknowledgment to Nabiximols correlates with the downregulation of allowed pathways in assorted sclerosis. Eur. J. Neurol. 25, 934–e70 (2018).
Orefice, N. S. et al. Oral palmitoylethanolamide assay is associated with bargain cutaneous adverse furnishings of interferon-beta1a and circulating proinflammatory cytokines in relapsing-remitting assorted sclerosis. Neurotherapeutics 13, 428–438 (2016).
Moreno-Martet, M. et al. Changes in endocannabinoid receptors and enzymes in the analgesic bond of SOD1(G93A) transgenic mice and appraisal of a Sativex®-like aggregate of phytocannabinoids: absorption for approaching therapies in amyotrophic crabbed sclerosis. CNS Neurosci. Ther. 20, 809–815 (2014).
Zhao, P. et al. Adapted presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS archetypal mice: implications for excitotoxicity. Eur. J. Neurosci. 27, 572–579 (2008).
Pasquarelli, N. et al. Appraisal of monoacylglycerol lipase as a ameliorative ambition in a transgenic abrasion archetypal of ALS. Neuropharmacology 124, 157–169 (2017).
Shoemaker, J. L. et al. The CB2 cannabinoid agonist AM-1241 prolongs adaptation in a transgenic abrasion archetypal of amyotrophic crabbed sclerosis back accomplished at affirmation onset. J. Neurochem. 101, 87–98 (2007).
Espejo-Porras, F. et al. Changes in the endocannabinoid signaling arrangement in CNS structures of TDP-43 transgenic mice: appliance for a neuroprotective assay in TDP-43-related disorders. J. Neuroimmune Pharmacol. 10, 233–244 (2015).
Espejo-Porras, F., Fernandez-Ruiz, J. & de Lago, E. Assay of endocannabinoid receptors and enzymes in the post-mortem motor case and analgesic bond of amyotrophic crabbed sclerosis patients. Amyotroph. Crabbed Scler. Frontotemporal Degener. 19, 377–386 (2018).
Witting, A. et al. Endocannabinoids accrue in analgesic bond of SOD1 G93A transgenic mice. J. Neurochem. 89, 1555–1557 (2004).
Rajan, T. S. et al. Gingival stromal beef as an in vitro model: cannabidiol modulates genes affiliated with amyotrophic crabbed sclerosis. J. Cell. Biochem. 118, 819–828 (2017).
Palma, E. et al. Acetylcholine receptors from beastly beef as pharmacological targets for ALS therapy. Proc. Natl Acad. Sci. USA 113, 3060–3065 (2016).
Clemente, S. Amyotrophic crabbed sclerosis assay with ultramicronized palmitoylethanolamide: a case report. CNS Neurol. Disord. Drug Targets 11, 933–936 (2012). The aboriginal abstraction to advance a ameliorative aftereffect of palmitoylethanolamide in ALS.
Donat, C. K. et al. Aboriginal access of cannabinoid receptor body afterwards beginning alarming academician abrasion in the bairn piglet. Acta Neurobiol. Exp. 74, 197–210 (2014).
Panikashvili, D. et al. CB1 cannabinoid receptors are complex in neuroprotection via NF-kappa B inhibition. J. Cereb. Claret Flow Metab. 25, 477–484 (2005).
Elliott, M. B. et al. Astute furnishings of a careful cannabinoid-2 receptor agonist on neuroinflammation in a archetypal of alarming academician injury. J. Neurotrauma 28, 973–981 (2011).
Amenta, P. S. et al. A cannabinoid blazon 2 receptor agonist attenuates blood-brain barrier accident and neurodegeneration in a murine archetypal of alarming academician injury. J. Neurosci. Res. 90, 2293–2305 (2012).
Panikashvili, D. et al. An autogenous cannabinoid (2-AG) is neuroprotective afterwards academician injury. Nature 413, 527–531 (2001).
Panikashvili, D. et al. The endocannabinoid 2-AG protects the blood-brain barrier afterwards bankrupt arch abrasion and inhibits mRNA announcement of proinflammatory cytokines. Neurobiol. Dis. 22, 257–264 (2006). The aboriginal abstraction to advance a careful role for endocannabinoids in academician trauma.
Tchantchou, F. et al. The blubbery acerbic amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates deepening and improves anatomic accretion in mice with alarming academician injury. Neuropharmacology 85, 427–439 (2014).
Tchantchou, F. & Zhang, Y. Careful inhibition of alpha/beta-hydrolase area 6 attenuates neurodegeneration, alleviates claret academician barrier breakdown, and improves anatomic accretion in a abrasion archetypal of alarming academician injury. J. Neurotrauma 30, 565–579 (2013).
Katz, P. S. et al. Endocannabinoid abasement inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation afterward balmy alarming academician injury. J. Neurotrauma 32, 297–306 (2015).
Mayeux, J. et al. Inhibition of endocannabinoid abasement improves outcomes from balmy alarming academician injury: a mechanistic role for synaptic hyperexcitability. J. Neurotrauma 34, 436–443 (2017).
Ahmad, A. et al. Administering of palmitoylethanolamide (PEA) protects the neurovascular assemblage and reduces accessory abrasion afterwards alarming academician abrasion in mice. Academician Behav. Immun. 26, 1310–1321 (2012).
Cohen-Yeshurun, A. et al. N-arachidonoyl-L-serine (AraS) possesses proneurogenic backdrop in vitro and in vivo afterwards alarming academician injury. J. Cereb. Claret Flow Metab. 33, 1242–1250 (2013).
Yang, D. X. et al. Inhibition of brief receptor abeyant vanilloid 1 attenuates blood–brain barrier disruption afterwards alarming academician abrasion in mice. J. Neurotrauma 36, 1279–1290 (2019).
Feigenbaum, J. J. et al. Nonpsychotropic cannabinoid acts as a anatomic N-methyl-D-aspartate receptor blocker. Proc. Natl Acad. Sci. USA 86, 9584–9587 (1989).
Maas, A. I. et al. Ability and assurance of dexanabinol in astringent alarming academician injury: after-effects of a actualization III randomised, placebo-controlled, analytic trial. Lancet Neurol. 5, 38–45 (2006).
Chi, O. Z. et al. Furnishings of cannabinoid receptor agonist WIN 55,212-2 on blood-brain barrier disruption in focal bookish ischemia in rats. Pharmacology 89, 333–338 (2012).
Mauler, F. et al. Neuroprotective and academician edema-reducing ability of the atypical cannabinoid receptor agonist BAY 38-7271. Academician Res. 989, 99–111 (2003).
Hayakawa, K. et al. Delta9-tetrahydrocannabinol (delta9-THC) prevents bookish infarction via hypothalamic-independent hypothermia. Life Sci. 80, 1466–1471 (2007).
Parmentier-Batteur, S. et al. Added severity of achievement in CB1 cannabinoid receptor knock-out mice. J. Neurosci. 22, 9771–9775 (2002).
Muthian, S. et al. Anandamide agreeable is added and CB1 cannabinoid receptor barricade is careful during transient, focal bookish ischemia. Neuroscience 129, 743–750 (2004).
Zarruk, J. G. et al. Cannabinoid blazon 2 receptor activation downregulates stroke-induced archetypal and another academician macrophage/microglial activation accessory to neuroprotection. Achievement 43, 211–219 (2012).
Zhang, M. et al. CB2 receptor activation attenuates microcirculatory dysfunction during bookish ischemic/reperfusion injury. Microvasc. Res. 78, 86–94 (2009).
Ward, S. J. et al. Surprising outcomes in cannabinoid CB1/CB2 receptor bifold knockout mice in two models of ischemia. Life Sci. 195, 1–5 (2018).
Schomacher, M. et al. Endocannabinoids arbitrate neuroprotection afterwards brief focal bookish ischemia. Academician Res. 1240, 213–220 (2008).
Sun, Y. et al. Cannabinoid activation of PPAR alpha; a atypical neuroprotective mechanism. Br. J. Pharmacol. 152, 734–743 (2007).
Yang, L. C. et al. Abiding oleoylethanolamide assay improves spatial bookish deficits through acceptable hippocampal neurogenesis afterwards brief focal bookish ischemia. Biochem. Pharmacol. 94, 270–281 (2015).
Schabitz, W. R. et al. Absolution of blubbery acerbic amides in a accommodating with hemispheric stroke: a microdialysis study. Achievement 33, 2112–2114 (2002).
Franklin, A. et al. Palmitoylethanolamide increases afterwards focal bookish ischemia and potentiates microglial corpuscle motility. J. Neurosci. 23, 7767–7775 (2003).
Naccarato, M. et al. Accessible anandamide and palmitoylethanolamide captivation in beastly stroke. Lipids Bloom Dis. 9, 47 (2010).
Mishima, K. et al. Cannabidiol prevents bookish infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Achievement 36, 1077–1082 (2005).
Khaksar, S. & Bigdeli, M. R. Anti-excitotoxic furnishings of cannabidiol are partly advised by accessory of NCX2 and NCX3 announcement in beastly archetypal of bookish ischemia. Eur. J. Pharmacol. 794, 270–279 (2017).
Alvarez, F. J. et al. Neuroprotective furnishings of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic bairn piglets. Pediatr. Res. 64, 653–658 (2008).
Castillo, A. et al. The neuroprotective aftereffect of cannabidiol in an in vitro archetypal of bairn hypoxic-ischemic academician accident in mice is advised by CB(2) and adenosine receptors. Neurobiol. Dis. 37, 434–440 (2010).
Lafuente, H. et al. Cannabidiol reduces academician accident and improves anatomic accretion afterwards astute hypoxia-ischemia in bairn pigs. Pediatr. Res. 70, 272–277 (2011).
Pazos, M. R. et al. Cannabidiol administering afterwards hypoxia-ischemia to bairn rats reduces abiding academician abrasion and restores neurobehavioral function. Neuropharmacology 63, 776–783 (2012).
Ceprian, M. et al. Cannabidiol reduces academician accident and improves anatomic accretion in a neonatal rat archetypal of arterial ischemic stroke. Neuropharmacology 116, 151–159 (2017).
Marinelli, L. et al. A randomised controlled cross-over double-blind pilot abstraction agreement on THC:CBD oromucosal aerosol ability as an add-on assay for post-stroke spasticity. BMJ Open 7, e016843 (2017).
Caltagirone, C. et al. Co-ultramicronized palmitoylethanolamide/luteolin in the assay of bookish ischemia: from rodent to man. Transl. Achievement Res. 7, 54–69 (2016).
Vinogradova, L. V. & van Rijn, C. M. Abiding disease-modifying aftereffect of the endocannabinoid agonist WIN55,212-2 in a rat archetypal of audiogenic epilepsy. Pharmacol. Rep. 67, 501–503 (2015).
Di Maio, R., Cannon, J. R. & Greenamyre, J. T. Post-status epilepticus assay with the cannabinoid agonist WIN 55,212-2 prevents abiding epileptic hippocampal accident in rats. Neurobiol. Dis. 73, 356–365 (2015).
Wallace, M. J. et al. The autogenous cannabinoid arrangement regulates access abundance and continuance in a archetypal of banausic affiliate epilepsy. J. Pharmacol. Exp. Ther. 307, 129–137 (2003).
Vinogradova, L. V., Shatskova, A. B. & van Rijn, C. M. Pro-epileptic furnishings of the cannabinoid receptor adversary SR141716 in a archetypal of audiogenic epilepsy. Attack Res. 96, 250–256 (2011).
Echegoyen, J. et al. Single appliance of a CB1 receptor adversary rapidly afterward arch abrasion prevents abiding hyperexcitability in a rat model. Attack Res. 85, 123–127 (2009).
Wang, X. et al. CB1 receptor animosity prevents abiding hyperexcitability afterwards arch abrasion by adjustment of dynorphin-KOR arrangement and mGluR5 in rat hippocampus. Academician Res. 1646, 174–181 (2016).
Feng, B. et al. Brief access of interleukin-1beta afterwards abiding delirious seizures promotes developed epileptogenesis through abiding upregulating endocannabinoid signaling. Sci. Rep. 6, 21931 (2016).
Wallace, M. J. et al. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur. J. Pharmacol. 428, 51–57 (2001).
Luszczki, J. J. et al. Furnishings of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate adjoin astute electroshock-induced seizures in mice. Eur. J. Pharmacol. 720, 247–254 (2013).
Payandemehr, B. et al. Captivation of PPAR receptors in the anticonvulsant furnishings of a cannabinoid agonist, WIN 55,212-2. Prog. Neuropsychopharmacol. Biol. Psychiatry 57, 140–145 (2015).
Bahremand, A. et al. Captivation of nitrergic arrangement in the anticonvulsant aftereffect of the cannabinoid CB(1) agonist ACEA in the pentylenetetrazole-induced access in mice. Attack Res. 84, 110–119 (2009).
Marsicano, G. et al. CB1 cannabinoid receptors and on-demand aegis adjoin excitotoxicity. Science 302, 84–88 (2003). The aboriginal abstraction to authenticate the on-demand neuroprotective role of endocannabinoids and CB1 adjoin excitotoxicity-induced neuronal damage.
Lerner, R. et al. Targeting academician and borderline bendability of the lipidome in astute kainic acid-induced epileptic seizures in mice via quantitative accession spectrometry. Biochim. Biophys. Acta Mol. Corpuscle Biol. Lipids 1862, 255–267 (2017).
Chen, K. et al. Abiding bendability of endocannabinoid signaling induced by adorning delirious seizures. Neuron 39, 599–611 (2003).
Vilela, L. R. et al. Furnishings of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole-induced access and electroencephalographic action in rats. Attack Res. 104, 195–202 (2013).
Shubina, L., Aliev, R. & Kitchigina, V. Attenuation of kainic acid-induced cachet epilepticus by inhibition of endocannabinoid carriage and abasement in guinea pigs. Attack Res. 111, 33–44 (2015).
Manna, S. S. & Umathe, S. N. Captivation of brief receptor abeyant vanilloid blazon 1 channels in the pro-convulsant aftereffect of anandamide in pentylenetetrazole-induced seizures. Attack Res. 100, 113–124 (2012).
Zareie, P. et al. Anticonvulsive furnishings of endocannabinoids; an analysis to actuate the role of authoritative apparatus of endocannabinoid metabolism in the pentylenetetrazol induced tonic- clonic seizures. Metab. Academician Dis. 33, 939–948 (2018).
Naydenov, A. V. et al. ABHD6 barricade exerts antiepileptic action in PTZ-induced seizures and in ad-lib seizures in R6/2 mice. Neuron 83, 361–371 (2014).
Griebel, G. et al. Careful barricade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs acquirements and anamnesis achievement while bearing antinociceptive action in rodents. Sci. Rep. 5, 7642 (2015).
Ma, L. et al. Disease-modifying furnishings of RHC80267 and JZL184 in a pilocarpine abrasion archetypal of banausic affiliate epilepsy. CNS Neurosci. Ther. 20, 905–915 (2014).
Shirazi, M. et al. Captivation of axial TRPV1 receptors in pentylenetetrazole and amygdala-induced activation in macho rats. Neurol. Sci. 35, 1235–1241 (2014).
Aghaei, I. et al. Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors. Attack Res. 117, 23–28 (2015).
Jones, N. A. et al. Cannabidiol displays antiepileptiform and antiseizure backdrop in vitro and in vivo. J. Pharmacol. Exp. Ther. 332, 569–577 (2010).
Jones, N. A. et al. Cannabidiol exerts anti-convulsant furnishings in beastly models of banausic affiliate and fractional seizures. Access 21, 344–352 (2012).
Khan, A. A. et al. Cannabidiol exerts antiepileptic furnishings by abating hippocampal interneuron functions in a banausic affiliate attack model. Br. J. Pharmacol. 175, 2097–2115 (2018).
Hill, A. J. et al. Cannabidivarin is anticonvulsant in abrasion and rat. Br. J. Pharmacol. 167, 1629–1642 (2012).
Thiele, E. A. et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut affection (GWPCARE4): a randomised, double-blind, placebo-controlled actualization 3 trial. Lancet 391, 1085–1096 (2018). One of two controlled analytic studies that led to the approval of botanical cannabidiol adjoin attenuate and untreatable forms of paediatric epilepsy.
Szaflarski, J. P. et al. Cannabidiol improves abundance and severity of seizures and reduces adverse contest in an open-label add-on -to-be study. Attack Behav. 87, 131–136 (2018).
Devinsky, O. et al. Open-label use of awful antiseptic CBD (Epidiolex®) in patients with CDKL5 absence ataxia and Aicardi, Dup15q, and Doose syndromes. Attack Behav. 86, 131–137 (2018).
Gofshteyn, J. S. Cannabidiol as a abeyant assay for delirious infection-related attack affection (FIRES) in the astute and abiding phases. J. Child. Neurol. 32, 35–40 (2017).
Gaston, T. E. et al. Interactions amid cannabidiol and frequently acclimated antiepileptic drugs. Epilepsia 58, 1586–1592 (2017).
De Jesus, M. L. et al. Opposite changes in cannabinoid CB1 and CB2 receptor announcement in beastly gliomas. Neurochem. Int. 56, 829–833 (2010).
Wu, X. et al. About-face of endocannabinoid arrangement in beastly gliomas. J. Neurochem. 120, 842–849 (2012).
Ellert-Miklaszewska, A., Ciechomska, I. & Kaminska, B. Cannabinoid signaling in glioma cells. Adv. Exp. Med. Biol. 986, 209–220 (2013).
Galve-Roperh, I. et al. Anti-tumoral action of cannabinoids: captivation of abiding ceramide accession and extracellular signal-regulated kinase activation. Nat. Med. 6, 313–319 (2000). The aboriginal abstraction to advance that THC could be acclimated in the assay of glioblastoma.
Blazquez, C. et al. Inhibition of bump angiogenesis by cannabinoids. FASEB J. 17, 529–531 (2003).
Gurley, S. N. et al. Apparatus of anti-glioma action and in vivo ability of the cannabinoid ligand KM-233. J. Neurooncol. 110, 163–177 (2012).
Sanchez, C. et al. Inhibition of glioma advance in vivo by careful activation of the CB(2) cannabinoid receptor. Blight Res. 61, 5784–5789 (2001).
Aguado, T. et al. Cannabinoids abet glioma stem-like corpuscle adverse and arrest gliomagenesis. J. Biol. Chem. 282, 6854–6862 (2007).
Ma, C. et al. Anti-carcinogenic action of anandamide on beastly glioma in vitro and in vivo. Mol. Med. Rep. 13, 1558–1562 (2016).
Stock, K. et al. Neural forerunner beef abet corpuscle afterlife of high-grade astrocytomas through dispatch of TRPV1. Nat. Med. 18, 1232–1238 (2012). The analysis that endocannabinoid-like mediators acting at TRPV1 could accept a role in the ascendancy of glioblastoma.
Nabissi, M. et al. Post-transcriptional adjustment of 5′-untranslated regions of beastly brief receptor abeyant vanilloid type-1 (TRPV-1) channels: role in the adaptation of glioma patients. Oncotarget 7, 81541–81554 (2016).
Vaccani, A. et al. Cannabidiol inhibits beastly glioma corpuscle clearing through a cannabinoid receptor-independent mechanism. Br. J. Pharmacol. 144, 1032–1036 (2005).
Moreno, E. et al. Targeting CB2-GPR55 receptor heteromers modulates blight corpuscle signaling. J. Biol. Chem. 289, 21960–21972 (2014).
Scott, K. A., Dalgleish, A. G. & Liu, W. M. The aggregate of cannabidiol and delta9-tetrahydrocannabinol enhances the anticancer furnishings of radiation in an orthotopic murine glioma model. Mol. Cancer. Ther. 13, 2955–2967 (2014).
Torres, S. et al. A accumulated preclinical assay of cannabinoids and temozolomide adjoin glioma. Mol. Cancer. Ther. 10, 90–103 (2011).
Nabissi, M. et al. Triggering of the TRPV2 approach by cannabidiol sensitizes glioblastoma beef to cytotoxic chemotherapeutic agents. Carcinogenesis 34, 48–57 (2013).
Nabissi, M. et al. Cannabidiol stimulates Aml-1a-dependent glial adverse and inhibits glioma stem-like beef admeasurement by inducing autophagy in a TRPV2-dependent manner. Int. J. Blight 137, 1855–1869 (2015).
GW Pharmaceuticals. GW Pharmaceuticals achieves absolute after-effects in actualization 2 affidavit of abstraction abstraction in glioma. gwpharm https://www.gwpharm.co.uk/about/news/gw-pharmaceuticals-achieves-positive-results-phase-2-proof-concept-study-glioma (2017).
US National Library of Medicine. Clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT01654497 (2017).
Chiurchiù, V. et al. Accentuation of monocytes by bioactive lipid anandamide in assorted sclerosis involves audible Toll-like receptors. Pharmacol. Res. 113, 313–319 (2016).
Franco, R. & Fernández-Suárez, D. Alternatively activated microglia and macrophages in the axial afraid system. Prog. Neurobiol. 131, 65–86 (2015).
Muller-Vahl, K. R. Assay of Tourette affection with cannabinoids. Behav. Neurol. 27, 119–124 (2013).
Ruzic Zecevic, D. et al. Investigational cannabinoids in access disorders, what accept we abstruse appropriately far? Expert Opin. Investig. Drugs 27, 535–541 (2018).
US National Library of Medicine. Clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT03202303 (2019).
Ganley, O. H., Graessle, O. E. & Robinson, H. J. Anti-inflammatory action on compounds acquired from egg yolk, peanut oil, and soybean lecithin. J. Lab. Clin. Med. 51, 709–714 (1958).
Guida, F. et al. Palmitoylethanolamide induces microglia changes associated with added clearing and phagocytic activity: captivation of the CB2 receptor. Sci. Rep. 7, 375 (2017).
Chiurchiù, V. et al. Resolution of deepening is adapted in abiding affection abortion and entails a abortive admiration of T lymphocytes. FASEB J. 33, 909–916 (2019).
Mestre, L. et al. Gut microbiota, cannabinoid arrangement and neuroimmune interactions: new perspectives in assorted sclerosis. Biochem. Pharmacol 157, 51–66 (2018).
Russo, R. et al. Gut-brain axis: role of lipids in the adjustment of inflammation, affliction and CNS diseases. Curr. Med. Chem. 25, 3930–3952 (2018).
Hata, T. et al. Adjustment of gut luminal serotonin by commensal microbiota in mice. PLOS ONE 12, e0180745 (2017).
Yunes, R. A. et al. GABA assembly and anatomy of gadB/gadC genes in Lactobacillus and Bifidobacterium strains from beastly microbiota. Anaerobe 42, 197–204 (2016).
Cohen, L. J. et al. Commensal bacilli accomplish GPCR ligands that actor beastly signalling molecules. Nature 549, 48–53 (2018).
Bell, J. S. et al. From adenoids to gut – the role of the microbiome in acoustic disease. Neuropathol. Appl. Neurobiol. 45, 195–215 (2019).
Veilleux, A., Di Marzo, V. and Silvestri, C. The broadcast endocannabinoid system/endocannabinoidome as a abeyant ambition for alleviative diabetes mellitus. Curr. Diabetes Rep. 19, 117 (2019).
Lutz, B. & Marsicano, G. in Encyclopedia of Neuroscience (eds Squire, L. R. et al.) 963–975 (Elsevier, 2009).
Müller, F. J., Snyder, E. Y. & Loring, J. F. Gene therapy: can neural axis beef deliver? Nat. Rev. Neurosci. 7, 75–84 (2006).
Hu, X. et al. Microglial and macrophage animosity — new affairs for academician repair. Nat. Rev. Neurol. 11, 56–64 (2015).
Expanded Form 5 Five Expanded Form 5 Tips You Need To Learn Now – expanded form 100
| Allowed to be able to the weblog, in this moment I will provide you with regarding keyword. And now, this is the 1st graphic: